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Nearly all human immunodeficiency virus (HIV) infections are acquired mucosally, and the gut-associated
lymphoid tissues are important sites for early virus replication. Thus, vaccine strategies designed to prime
virus-specific cytotoxic T lymphocyte (CTL) responses that home to mucosal compartments may be particularly
effective at preventing or containing HIV infection. The Salmonella type III secretion system has been shown to
be an effective approach for stimulating mucosal CTL responses in mice. We therefore tested phoP-phoQ
attenuated strains of Salmonella enterica serovar Typhimurium and S. enterica serovar Typhi expressing
fragments of the simian immunodeficiency virus (SIV) Gag protein fused to the type III-secreted SopE protein
for the ability to prime virus-specific CTL responses in rhesus macaques. Mamu-A*01 macaques were
inoculated with three oral doses of recombinant Salmonella, followed by a peripheral boost with modified
vaccinia virus Ankara expressing SIV Gag (MVA Gag). Transient low-level CTL responses to the Mamu-A*01
Gag181-189 epitope were detected following each dose of Salmonella. After boosting with MVA Gag, strong
Gag-specific CTL responses were consistently detected, and tetramer staining revealed the expansion of
Gag181-189-specific CD8
 T-cell responses in peripheral blood. A significant percentage of the Gag181-189-
specific T-cell population in each animal also expressed the intestinal homing receptor 47. Additionally,
Gag181-189-specific CD8
 T cells were detected in lymphocytes isolated from the colon. Yet, despite these
responses, Salmonella-primed/MVA-boosted animals did not exhibit improved control of virus replication
following a rectal challenge with SIVmac239. Nevertheless, this study demonstrates the potential of mucosal
priming by the Salmonella type III secretion system to direct SIV-specific cellular immune responses to the
gastrointestinal mucosa in a primate model.
Sexual transmission across mucosal barriers is by far the
most common mode of human immunodeficiency virus (HIV)
infection. Furthermore, the gut-associated lymphoid tissues
are a major source of virus replication during the first few
weeks of infection (39). These observations suggest that vac-
cine strategies designed to maximize virus-specific immune
responses at mucosal barriers and in mucosal lymphoid tissues
may be particularly effective at preventing or containing infec-
tions early, before diversification and dissemination of the vi-
rus population.
Peripheral vaccine strategies based on prime and boost reg-
imens with recombinant DNA and/or virus vectors can elicit
potent cellular immune responses to simian immunodeficiency
virus (SIV) and HIV-1 antigens (3, 6, 11, 28, 31, 35). These
approaches also afford limited protection, as measured by re-
ductions in peak and postacute viral loads following challenges
with pathogenic SIV strains or simian-human immunodefi-
ciency virus (SHIV) chimeras (3, 6, 11, 28, 31, 35). Higher
frequencies of virus-specific CD8 T lymphocytes and the
stimulation of CD4 T helper cell responses were generally
associated with better control of viral loads after challenge (3,
6, 31, 35). Thus, while both antibody and cellular immune
responses may ultimately be required for optimal protection,
these studies indicate that strong cellular immune responses
induced by vaccination can serve to limit virus replication.
Since immunization by peripheral routes typically does not
induce immune responses in mucosal compartments (7, 10,
12), the protection afforded by prime and boost regimens could
potentially be improved by modifications that direct cellular
immune responses to mucosal sites. In support of this idea, a
direct comparison of intrarectal versus subcutaneous immuni-
zation with similar peptide formulations demonstrated better
protection of mucosally immunized animals against an intra-
rectal SHIV challenge (8). In this study, protection, as mea-
sured by reduced postchallenge viral loads, correlated with the
stimulation of both virus-specific cytotoxic T lymphocyte
(CTL) and T helper cell responses (8).
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Attenuated strains of Salmonella spp. have been developed
as potential vectors for stimulating immune responses in the
gastrointestinal mucosa (34). However, the confinement of Sal-
monella strains to the intracellular vesicular compartments of
bacterially infected cells has limited their potential for stimu-
lating major histocompatibility complex (MHC) class I-re-
stricted CTL responses. Indeed, this may explain the inefficient
stimulation of virus-specific CTL responses in earlier studies in
which macaques were immunized with recombinant Salmo-
nella strains engineered to express SIV antigens (13, 37). To
circumvent this problem, we have used an approach that takes
advantage of the bacterial type III secretion system to deliver
vaccine antigens directly into the cytoplasm and into the MHC
class I antigen-processing pathway of Salmonella-infected cells
(33).
The Salmonella type III secretion system is a multicompo-
nent system consisting of structural, regulatory, and secreted
elements specialized for the delivery of bacterial proteins into
eukaryotic host cells (14). Upon contact with mammalian cells,
structural elements of the Salmonella type III secretion system
assemble into needle-like molecular filaments that span the
inner and outer bacterial membranes and traverse the plasma
membrane of the mammalian cell. By fusing heterologous pro-
tein sequences to type III-secreted bacterial proteins, antigens
may be efficiently targeted into the host cell cytoplasm for
antigen processing and presentation in association with MHC
class I molecules (33). Infection with Salmonella recombinants
expressing immunodominant CTL epitopes of influenza virus
and lymphocytic choriomeningitis virus as fusions with the
bacterial SptP protein has been shown to sensitize cells for
CTL recognition in vitro (33). CTL recognition was MHC class
I restricted, TAP dependent, and dependent on bacterial trans-
location of the SptP fusions by the type III secretion pathway
(33). Furthermore, immunization of mice with an attenuated
Salmonella strain engineered to deliver a single immunodom-
inant CTL epitope of lymphocytic choriomeningitis virus stim-
ulated potent virus-specific CTL responses that protected
against a lethal challenge with lymphocytic choriomeningitis
virus (33).
Here we explore the potential of the Salmonella type III
secretion system to stimulate SIV-specific CTL responses in
the gastrointestinal mucosa of rhesus macaques. Our data
show for the first time that the Salmonella type III secretion
system can be used to deliver large polypeptide antigens rather
than minimal CTL epitopes for MHC class I antigen process-
ing and presentation. This study is also the first to demonstrate
the ability of the Salmonella type III antigen delivery system to
prime T-cell responses in a nonhuman primate model and
provides an important proof of principle for the feasibility of
mucosal prime/peripheral boost vaccine approaches to direct
cellular immune responses to mucosal compartments.
MATERIALS AND METHODS
Salmonella type III secretion constructs. A panel of constructs expressing
fusions between the SIV Gag protein and the bacterial SopE protein were
created for the delivery of Gag polypeptides into mammalian cells by the Sal-
monella type III secretion system. Sequences coding for amino acids 4 to 507, 4
to 439, 4 to 284, 146 to 213, and 267 to 507 of Gag were cloned downstream from
the sequence encoding the promoter and the first 104 amino acids of SopE in the
low-copy plasmid pWSK30 (30, 41). The H-2b-restricted influenza virus nucleo-
protein epitope NP366-374 was included between the SopE and Gag sequences to
enable the detection of antigen presentation in murine cells. phoP-phoQ atten-
uated strains of Salmonella enterica serovar Typhimurium (8429) and Salmo-
nella enterica serovar Typhi (8521) were transformed with each of these con-
structs to create SopE-Gag-expressing Salmonella recombinants (15).
Generation of modified vaccinia virus Ankara SIVmac239 gag recombinant.
The parental vaccinia virus was a plaque-purified isolate of a replication-defec-
tive strain of vaccinia virus designated modified vaccinia virus Ankara (MVA)
(25). Recombinant MVA virus vT338 contains the gag gene from SIVmac239
(30) inserted into the deletion III region of the MVA genome (26) under the
control of the vaccinia virus 40K (H5R) promoter (17). The virus also contains
the Escherichia coli lacZ gene under the control of the fowlpox C1 promoter (21)
for use as a colorimetric screen for recombinant viruses. The genomic structure
of the recombinant virus was determined by amplification by PCR. Expression of
Gag p55 was demonstrated by Western blot assay with anti-p27 antibody (Ad-
vanced Biotechnologies, Inc.).
Animals and housing. Rhesus macaques (Macaca mulatta) were housed at the
New England Regional Primate Research Center in a centralized animal bio-
safety level 3 containment facility in accordance with standards of the Associa-
tion for Assessment and Accreditation of Laboratory Animal Care and the
Harvard Medical School Animal Care and Use Committee. Research was con-
ducted according to the principles described in the Guide for the Care and Use
of Laboratory Animals (4) and was approved by the Harvard Medical School
Animal Care and Use Committee. Animals positive for the MHC class I allele
Mamu-A*01 were identified by sequence-specific PCR (22) and selected for this
study. All animals were also tested and found to be free of simian retrovirus type
D, SIV, simian T lymphotropic virus type 1, and herpes B virus prior to assign-
ment. Additionally, animals were screened and found to be negative for Salmo-
nella-specific antibodies in serum. Over the course of the study, animals were
monitored closely and euthanized when they were moribund or it was deemed
necessary by the veterinary staff.
Salmonella strains and MVA inoculations. Two Mamu-A*01 rhesus ma-
caques were inoculated with three intragastric doses of an attenuated Salmonella
strain expressing SopE-Gag and boosted peripherally with MVA Gag (vT338;
Therion Biologics Corporation, Cambridge, Mass.). Salmonella cultures were
grown at 37°C with gentle shaking from an overnight starter culture in modified
Luria-Bertani (LB) medium containing 0.3 M NaCl and 100 g of ampicillin per
ml to late log phase (0.8 to 0.9 optical density units at 600 nm [OD600]). The
bacteria were then pelleted and resuspended in 2 ml of phosphate-buffered
saline. Bacterial suspensions were infused directly into the duodenum of anes-
thetized animals that had been treated with a solution of 0.5% sodium bicar-
bonate to prevent the loss of the inoculum due to exposure to stomach acids (36).
Each animal was given two doses of S. enterica serovar Typhimurium, consist-
ing of a 1:1 mixture of bacteria expressing SopE-Gag146-213 and SopE-Gag4-507 (5
 1010 CFU) on weeks 0 and 10. On week 27, each animal received an additional
dose of S. enterica serovar Typhi (5  109 CFU) expressing SopE-Gag146-213 and
SopE-Gag4-284. On week 40, the two Salmonella strain-primed animals and two
additional Mamu-A*01 control animals were boosted intradermally with 5 
108 PFU of MVA Gag suspended in 0.5 ml of phosphate-buffered saline as
described previously (2, 19).
Analysis of Salmonella shedding. The duration of Salmonella shedding in the
feces was monitored following each bacterial inoculation. Fecal samples were
collected and resuspended in selenite broth (1 g per 10 ml). Serial log dilutions
(101 to 109) were spread on duplicate MacConkey agar plates (50 l/plate)
with and without ampicillin (100 g/ml) and incubated overnight at 37°C. Plates
with ampicillin selected for the plasmid-containing Salmonella strain, while
plates without ampicillin were permissive for the growth of bacteria that had lost
the SopE-Gag expression construct during growth in vivo. Selenite broth cultures
were also incubated overnight at 37°C to enrich for Salmonella organisms present
at low frequencies. Overnight selenite broth cultures were plated to MacConkey
agar when Salmonella colonies were not observed at the lowest dilutions for the
initial set of plates. Non-lactose-fermenting colonies were selected for biochem-
ical confirmation as Salmonella strains with the RapiD 20E assay (BioMérieux,
Lyon, France). The last dilution positive for Salmonella colonies was scored to
obtain a semiquantitative estimate of the number of organisms present in the
feces at each time point.
CTL assays. (i) CTL recognition of Salmonella-infected cells. Mamu-A*01
B-lymphoblastoid cell lines (B-LCLs) were infected at an multiplicity of infection
of 40 CFU/cell with recombinant Salmonella strain grown to 0.8 to 0.9 OD600.
Cells (106) were infected for 2 h in 200 l of antibiotic-free R10 medium (RPMI
1640 with 10% fetal bovine serum) and labeled with 50 Ci of sodium
[51Cr]chromate during the second hour of incubation. B-LCLs pulsed with the
Mamu-A*01 Gag181-189 peptide (CTPYDINQM) and an irrelevant Nef peptide,
3K (ARGETYGRL), were also labeled as positive and negative controls, respec-
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tively. 51Cr-labeled B-LCL targets were then washed three times in R10 medium
with gentamicin (100 g/ml) to kill extracellular bacteria and to remove excess
[51Cr]chromium.
CTL lines were derived from SIV-infected Mamu-A*01 macaques by peptide
stimulation as described previously (28) and plated with 51Cr-labeled B-LCLs at
effector-to-target cell ratios of 40:1, 20:1, and 10:1. Unlabeled B-LCLs infected
with wild-type vaccinia virus (NYCBH) were added at a 15:1 unlabeled-to-
labeled target cell ratio to reduce nonspecific 51Cr release. After 4 h at 37°C, 30
l of supernatant was harvested from each well into the wells of a LumaPlate-96
(Packard), and emitted radioactivity was measured in a 1450 Microeta Plus
Liquid scintillation counter (Wallac, Turku, Finland). The percent specific 51Cr
release was calculated by the standard formula percent lysis  [(cpm with
effectors  spontaneous cpm)/(maximal cpm  spontaneous cpm)]  100.
(ii) Gag-specific CTL activity following immunization. Freshly isolated periph-
eral blood mononuclear cells (PBMC) (5  106/ml) were stimulated directly with
the Mamu-A*01 Gag181-189 peptide (1 g/ml) or by coculture with peptide-
pulsed, 	-irradiated (3,000 rad) autologous B-LCLs (10:1 PBMC to B-LCL ratio)
in multiple wells of a 24-well plate. After 4 days, recombinant human interleu-
kin-2 (generously provided by M. Gately, Hoffmann-La Roche, Nutley, N.J.) was
added to 20 U/ml, and cultures were incubated for 1 week to expand the
peptide-specific CTL population. CTL recognition of peptide-pulsed autologous
B-LCLs was assessed after 10 to 14 days of culture at three different effector-
to-target cell ratios in a 5-h chromium release assay as described above.
Proliferation assays. PBMC were stimulated in quadruplicate wells of a 24-
well plate (105 cells/well) with concanavalin A (5 g/ml; Sigma, St. Louis, Mo.),
p55 Gag (1 g/ml; provided by Shabbir Ahmad, University of California, Davis),
or aldrithiol-2-inactivated SIVmneE11S (E11S; 1 g of p27 CA equivalent per
ml) (5). PBMC controls were also incubated in R10 medium alone or with
mock-treated H9 supernatant because E11S was harvested from SIV-infected H9
cells. Five days after concanavalin A stimulation and 7 days after antigen stim-
ulation, cultures were pulsed with [3H]thymidine (1 Ci) for 6 h and then
harvested with an automated cell harvester (Tomtec; Wallac). [3H]thymidine
incorporation was determined with a Microeta Plus liquid scintillation counter
(Wallac). Antigen-specific proliferation, expressed as the stimulation index, was
calculated by dividing the mean [3H]thymidine incorporation in antigen-stimu-
lated wells by the mean incorporation in control wells.
Lymphocyte isolation from colon biopsies. Endoscope-guided biopsy samples
were collected from multiple sites in the colon to monitor for the homing of
SIV-specific CD8 T cells to the gastrointestinal mucosa with previously de-
scribed techniques (40). Pooled biopsy specimens from 10 to 12 separate sites
representing both the epithelium and the underlying lamina propria were incu-
bated in 1 mM EDTA for 30 min, followed by one hour in 0.5 mg of type II
collagenase (Sigma) per ml at 37°C with vigorous shaking. Tissues were then
mechanically dispersed with a blunt-ended 18-gauge needle and filtered through
a 70-m nylon cell strainer. Cell suspensions were then layered over 35% to 60%
discontinuous Percoll gradients and centrifuged at 1,000  g for 20 min at 4°C to
separate the lymphocytes and epithelial cells. Enriched lymphocyte populations
were collected from the interface between the Percoll layers, washed, and resus-
pended in fluorescence-activated cell sorting (FACS) buffer (phosphate-buffered
saline with 2% fetal bovine serum).
Flow cytometry. Peripheral blood and colonic lymphocytes were analyzed by
four-color flow cytometry for SIV-specific CD8 T cells. Whole blood (100 l)
or colonic lymphocytes (1  106 to 2  106 cells) were stained for 25 min at 37°C
with fluorescein isothiocyanate, peridinin chlorophyll protein, or phycoerythrin-
conjugated monoclonal antibodies and allophycocyanin-conjugated tetramers.
Cells were stained simultaneously with CD3-fluorescein isothiocyanate (Becton
Dickinson, San Jose, Calif.), CD8-peridinin chlorophyll protein (Becton Dickin-
son), and 
47-phycoerythrin (generously provided by Millennium Pharmaceu-
ticals, Cambridge, Mass.) monoclonal antibodies and either Mamu-A*01
Gag181-189 or Mamu-A*01 Tat28-35 tetramers (generously provided by John Alt-
man, Emory University, Atlanta, Ga.). Whole blood samples were treated for 10
min after antibody staining with FACS lysing solution (Becton Dickinson) to
remove erythrocytes. Cells were then washed once in FACS buffer and fixed in
2% paraformaldehyde–phosphate-buffered saline. Samples were analyzed on a
FACSCalibur flow cytometer (Becton Dickinson), and data analysis was per-
formed with FlowJo (Tree Star, San Carlos, Calif.).
Intrarectal challenge. Macaques were challenged intrarectally with a dose of
8.5 ng of p27 equivalents (103.5 50% tissue culture infectious doses) of
SIVmac239 (23). The anal area of anesthetized animals was gently cleansed with
soap and water, and the pelvis was elevated to an approximately 45° angle. The
inoculum was drawn into a 1-ml syringe fitted with a 2-in. (ca. 5-cm) gastric
gavage tube lubricated with KY jelly. The tube was gently inserted into the
rectum to prevent abrasion or tearing of the epithelium, and the inoculum was
gradually infused into the rectal cavity. After infusion, the pelvis was kept in an
elevated position for approximately 10 min to prevent drainage of the inoculum.
Viral loads and CD4 counts. SIV loads in plasma were quantitated with a
real-time reverse-transcriptase-PCR assay as previously described (24). CD4
counts were determined by flow cytometry as previously described (43).
RESULTS
CTL recognition of rhesus monkey cell lines infected with
SopE-Gag recombinant Salmonella strains. Attenuated
phoP-phoQ strains of S. enterica serovar Typhimurium and S.
enterica serovar Typhi were engineered to deliver SIV Gag
polypeptides into the MHC class I antigen-processing pathway
of mammalian cells via the bacterial type III secretion system.
A panel of five type III-secretion constructs expressing fusions
between the first 104 amino acids of the Salmonella SopE
protein and different segments of the SIV Gag protein
were created. Four of the constructs (SopE-Gag4-507, SopE-
Gag4-439, SopE-Gag4-284, and SopE-Gag146-213) included the
immunodominant Gag181-189 CTL epitope bound by the rhesus
macaque MHC class I molecule Mamu-A*01 (1, 27), while a
fifth construct (SopE-Gag267-507) did not include this epitope.
To identify the most promising bacterial strains and con-
structs for immunizing animals, rhesus B-cell lines were in-
fected with phoP-phoQ attenuated strains of S. enterica sero-
var Typhimurium and S. enterica serovar Typhi expressing each
of the SopE-Gag fusions and tested for recognition by CTL
lines derived from SIV-infected, Mamu-A*01 animals (Fig.
1A and B). Delivery of each of the SopE-Gag fusions spanning
the Mamu-A*01/Gag181-189 epitope by S. enterica serovar Ty-
phimurium efficiently sensitized target cells for CTL recogni-
tion (Fig. 1A). However, CTL recognition of S. enterica serovar
Typhi-infected target cells was considerably less efficient.
There was no detectable CTL recognition of SopE-Gag4-507
and SopE-Gag4-439 in S. enterica serovar Typhi-infected cells
(Fig. 1B). Only SopE-Gag4-284 and SopE-Gag146-213 were rec-
ognized above background levels (Fig. 1B). These results in-
dicate that, at least in vitro, the S. enterica serovar Typhi-
murium recombinants are better able to sensitize rhesus cells
for CTL recognition than the S. enterica serovar Typhi recom-
binants. These observations are also consistent with assays
performed in rodent cells suggesting that the larger SopE-Gag
fusions may not be translocated into cells as efficiently as the
shorter fusions (data not shown).
We also tested CTL lines derived from an SIV-infected
Mamu-A*01 animal for the ability to recognize additional,
non-Mamu-A*01-restricted Gag epitopes. CTL lines were de-
rived from PBMC by stimulation with a recombinant vaccinia
virus expressing the full-length SIV Gag protein (Vac Gag)
and with peptides representing previously defined CTL
epitopes in this animal (Gag196-204 and Gag299-307). Each of the
CTL lines was tested for recognition of autologous B-cell tar-
gets infected with S. enterica serovar Typhimurium expressing
SopE-Gag4-507, SopE-Gag146-213, SopE-Gag267-507, and the
SopE vector. While the Vac Gag-stimulated CTL line killed
target cells infected with each of the SopE-Gag recombinants,
recognition by the peptide-stimulated CTL lines was more
specific. The Gag196-204-stimulated CTL line killed target cells
infected with S. enterica serovar Typhimurium expressing
SopE-Gag4-507 and SopE-Gag146-213 but not SopE-Gag267-507
(Fig. 1C). Likewise, the Gag299-307-stimulated CTL line killed
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target cells infected with S. enterica serovar Typhimurium ex-
pressing SopE-Gag4-507 and SopE-Gag267-507 but not SopE-
Gag146-213 (Fig. 1C). These results demonstrate that the Sal-
monella type III secretion system is capable of delivering
complex polypeptide antigens for MHC class I antigen pro-
cessing and presentation of multiple epitopes. Thus, CTL re-
sponses elicited by immunization with SopE-Gag recombinant
Salmonella need not be limited to the Mamu-A*01/Gag181-189
epitope.
Inoculations with recombinant Salmonella strains and MVA.
Based on CTL recognition in vitro, we selected S. enterica
serovar Typhimurium as the bacterial platform for the initial
priming doses. To maximize Mamu-A*01/Gag181-189-specific
CTL responses and to broaden T-cell responses to additional
Gag epitopes, a combination of bacteria expressing SopE-
Gag146-213 and SopE-Gag4-507 was used for immunization. Two
Mamu-A*01 macaques were inoculated with an equal mix-
ture of phoP-phoQ attenuated S. enterica serovar Typhi-
murium expressing SopE-Gag146-213 and SopE-Gag4-507 for
a total dose of 5  1010 CFU. An identical dose of
SopE-Gag146-213 and SopE-Gag4-507 recombinant S. enterica
serovar Typhimurium was administered 10 weeks later. Rea-
soning that we might minimize Salmonella-specific immunity
and enhance Gag-specific responses by switching bacterial
platforms, phoP-phoQ attenuated S. enterica serovar Typhi
was used for a second boost on week 27. Since there was no
detectable CTL recognition of SopE-Gag4-507 in S. enterica
serovar Typhi-infected cells (Fig. 1B), SopE-Gag4-284 was used
in place of SopE-Gag4-507. Each animal was inoculated with an
equal mixture of bacteria expressing SopE-Gag146-213 and
SopE-Gag4-284 for a total of 5  10
9 CFU. At week 40, each of
the Salmonella-primed animals and two additional Mamu-
A*01 control animals were boosted intradermally with an
MVA recombinant expressing the full-length SIV Gag protein.
Following each dose of recombinant Salmonella cells, bac-
terial shedding was monitored in the feces to confirm gastro-
intestinal exposure and to approximate the duration of Salmo-
nella infection. Fecal samples were collected periodically after
inoculation, and serial dilutions were plated to MacConkey
agar with and without ampicillin to assess the stability of the
SopE-Gag expression plasmids in vivo. There was a marked
difference between the two animals in clinical signs and dura-
tion of shedding following the first S. enterica serovar Typhi-
murium inoculation (Table 1). Animal 478.99 showed no signs
of clinical infection and resolved Salmonella infection within 1
week. However, animal 537.99 developed a severe case of
diarrhea that resulted in significant weight loss and continued
to shed S. enterica serovar Typhimurium for 4 weeks.
Following the S. enterica serovar Typhimurium and S. en-
terica serovar Typhi boosts at weeks 10 and 27, respectively, no
adverse clinical signs were observed in either animal. Shedding
after the week 10 boost ceased by 2 weeks postinoculation.
FIG. 1. CTL recognition of rhesus B-cell lines infected with attenuated strains of Salmonella expressing SopE-Gag fusion proteins. Mamu-
A*01 target cells were infected with phoP-phoQ attenuated S. enterica serovar Typhimurium (A) or S. enterica serovar Typhi (B) and tested for
recognition by CTL lines derived from an SIV-infected, Mamu-A*01 animal. Positive (Gag181-189 peptide) and negative (no peptide or unrelated
peptide [Nef23-31]) control targets were also included (A and B). CTL lines derived from an SIV-infected, Mamu-A*01
 animal by stimulation of
PBMC with vaccinia virus Gag (Vac Gag) or previously defined Gag epitopes (Gag196-204 and Gag299-307) were also tested for the ability to
recognize target cells infected with SopE-Gag-recombinant, attenuated S. enterica serovar Typhimurium (C).
TABLE 1. Salmonella shedding in feces of macaques
postinoculation
Day
Dilution of fecesa
S. enterica serovar Typhimurium S. entericaserovar Typhi
Wk 0 Wk 10 Wk 27
Animal
478.99
Animal
537.99
Animal
478.99
Animal
537.99
Animal
478.99
Animal
537.99
1 5 6 0 6 3 2
2 5 6 6 5 1 
3 6 4 ND ND 0 0
4 3 7 4  ND ND
6 ND ND ND ND 0 0
7 0 6 ND ND ND ND
8 ND ND  ND 0 0
9 ND 2 ND  1 0
10 ND ND 1 0 0 0
11 0 2 ND ND ND ND
14 0  0 0 ND ND
16 ND 2 0 0 ND ND
18 ND  ND ND ND ND
21 ND 1 ND ND ND ND
28 ND  ND ND ND ND
35 ND 0 ND ND ND ND
42 ND 0 ND ND ND ND
a Fecal samples were collected on the indicated days postinoculation, and
serial log dilutions were plated on MacConkey agar with ampicillin (100 g/ml).
Values represent the inverse of the exponent for the last dilution positive for
Salmonella (e.g., 5  105). 0, no Salmonella was recovered. , positive only
after overnight enrichment in selenite broth. ND, no sample was collected.
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Likewise, with the exception of a single sample from animal
478.99 on day 9, S. enterica serovar Typhi shedding was
resolved within 1 week postinoculation in both animals (Table
1). No differences in the frequency of Salmonella recov-
ery on plates with and without ampicillin were observed
(data not shown). Western blot analysis of Salmonella colo-
nies recovered from fecal cultures revealed the expression
SopE-Gag146-213 and SopE-Gag4-507 at roughly equivalent fre-
quencies after more than 3 weeks in animal 537.99 (data not
shown). Thus, the plasmids encoding the SopE-Gag fusions
were maintained well during bacterial replication in vivo in the
absence of antibiotic selection.
Salmonella-specific antibody responses also confirmed infec-
tion with S. enterica serovar Typhimurium. Preimmune serum
from each animal was negative for Salmonella-specific antibod-
ies. However, S. enterica serovar Typhimurium lipopolysaccha-
ride-specific antibody responses were detectable 1 week after
the first inoculation in both animals and increased following
the second inoculation at week 10 (data not shown). However,
there was no increase in antibody responses after the S. en-
terica serovar Typhi boost at week 27, possibly due to the
rather limited course of infection with this strain (data not
shown and Table 1).
SIV Gag-specific CD8 CTL responses. Peptide-stimulated
CTL cultures were derived from peripheral blood, and Gag-
specific CTL responses were measured by 51Cr release assays.
CTL responses directed against the Gag181-189 epitope ranging
from 5% to 25% specific release above background were ob-
served following each dose of recombinant Salmonella (Fig.
2A). Staining of these peptide-stimulated T cells with Mamu-
A*01/Gag181-189 tetramers confirmed the expansion of a Gag-
specific CD8 T-cell population at multiple time points in
animal 478.99 (data not shown). After the MVA Gag boost,
CTL activity was consistently observed in both of the Salmo-
nella-primed animals and in control animals immunized with
MVA Gag alone. Although CTL responses were somewhat
higher at three of five time points in the Salmonella-primed
animals compared to the animals that received only MVA Gag,
these results did not clearly differentiate between primary and
secondary responses in these two groups of animals (Fig. 2A).
However, this was not surprising because 51Cr release assays
are not a particularly quantitative method for measuring CTL
responses in vivo.
Peripheral blood lymphocytes were also stained directly with
Mamu-A*01/Gag181-189 tetramers as a more quantitative
method for following the development of Gag-specific CD8
T-cell responses. During the Salmonella-priming phase, the
frequency of Gag-specific CD8 T cells was below the thresh-
old of detection in both animals 478.99 and 537.99. However,
after boosting with MVA Gag, tetramer-positive CD8 T-cell
populations were detectable in all four animals (Fig. 2B). Fur-
thermore, there was a clear difference in the kinetics and
magnitude of these responses between the Salmonella-primed
animals and the animals that received only MVA Gag. Both of
the macaques that were inoculated with recombinant Salmo-
nella, 478.99 and 537.99, were tetramer positive (0.1% of the
CD8 T-cell population) at week 41, 1 week after the MVA
Gag boost. In contrast, tetramer-positive T-cell responses were
undetectable until weeks 42 and 43 in animals 334.95 and
256.90, respectively, that had received only MVA Gag (Fig.
2B). The frequency of Gag-specific CD8 T cells was also
considerably higher in the Salmonella-primed animals than in
the MVA Gag controls. While frequencies varied from one
time point to the next, at week 43, when all four animals had
detectable Gag-specific CD8 T-cell responses, the percentage
of tetramer-positive cells was 4- to 10-fold higher in the Sal-
monella-primed animals than in the animals immunized with
FIG. 2. SIV Gag-specific CD8 T-cell responses following immu-
nization with recombinant Salmonella and modified vaccinia virus An-
kara (MVA) expressing SIV Gag. Gag-specific CD8 T-cell responses
were followed by 51Cr release assays (A) and tetramer staining (B).
The solid arrows indicate inoculations with S. enterica serovar Typhi-
murium given at weeks 0 and 10, the dashed arrow indicates the S.
enterica serovar Typhi inoculation at week 27, and the double arrow
indicates the MVA Gag boost at week 40. NT indicates that samples
were not tested at week 10. (A) CTL cultures were derived from
PBMC by peptide stimulation and tested for CTL recognition of au-
tologous B-cell lines pulsed with Gag181-189 in
51Cr release assays. Bars
indicate the difference in percent specific release for target cells pulsed
with Gag181-189 and targets pulsed with an unrelated Nef peptide at the
highest effector-to-target cell ratio tested for each time point (20:1 to
40:1). Differences of greater than 10% specific release are considered
positive. (B) PBMC were stained with monoclonal antibodies to CD3
and CD8 and with Mamu-A*01/Gag181-189 tetramers and analyzed by
flow cytometry. After gating on the CD3 CD8 population, the per-
centage of tetramer-positive cells was determined at each time point.
Values greater than 0.1% are considered significant.
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MVA Gag alone. Thus, these observations are consistent with
the expansion of secondary CD8 T-cell responses to Gag in
the Salmonella-primed animals.
SIV-specific proliferative responses. Proliferative responses
to exogenous SIV antigens were monitored as an indicator of
the development of Gag-specific CD4 T-cell responses. Fresh
PBMC were stimulated with aldrithiol-inactivated prepara-
tions of SIV (5), and antigen-specific proliferation was assessed
by [3H]thymidine incorporation. Stimulation indexes were cal-
culated by dividing the [3H]thymidine incorporation in re-
sponse to antigen by the basal level of incorporation for PBMC
treated with control medium, and stimulation index values
greater than 3 were considered positive (Fig. 3).
SIV-specific proliferative responses were low in both ani-
mals after the initial priming dose of S. enterica serovar Typhi-
murium. However, after the second S. enterica serovar Typhi-
murium dose at week 10, robust proliferative responses were
observed in both animals for 3 weeks after inoculation (Fig. 3).
Stimulation indexes ranged between 5 and 20, which are com-
parable to T-cell proliferative responses observed in animals
chronically infected with live, attenuated strains of SIV (16).
Thus, these results clearly demonstrate the stimulation of vi-
rus-specific CD4 T-cell responses by SopE-Gag-recombinant
S. enterica serovar Typhimurium. However, with the exception
of two time points for animal 537.99, proliferative responses
after the S. enterica serovar Typhi boost at week 27 were
undetectable (Fig. 3). While the reasons for this are unclear,
the decision to use SopE-Gag4-284 rather than SopE-Gag4-507
and to lower the immunizing dose of the Salmonella strain
10-fold may have resulted in less efficient stimulation of Gag-
specific CD4 T-cell responses in animals 478.99 and 537.99.
Likewise, proliferative responses after the week 40 MVA Gag
boost were also low compared to responses following the sec-
ond dose of S. enterica serovar Typhimurium in these two
animals (Fig. 3). Since MVA Gag potently stimulated CD8
T-cell responses, the less efficient boosting of CD4 T-cell
responses may reflect a more effective stimulation of CD8
T-cell responses than CD4 T-cell responses.
Gag-specific CD8 T cells induced following Salmonella/
MVA vaccination express the mucosal homing receptor 47.
As a marker for mucosal homing, peripheral blood lympho-
cytes were stained with antibodies to 
47. 
47 is an integrin
expressed on lymphocytes specific for gastrointestinal patho-
gens and binds to the mucosal addressin cell adhesion mole-
cule (MadCAM1) expressed on high endothelial venules serv-
ing the gastrointestinal mucosa (9, 32, 38). Interactions
between 
47 and MadCAM1 participate in the migration of
lymphocytes out of the circulatory system and into mucosal
tissues (18, 42). Thus, 
47 represents a convenient surface
marker for lymphocytes homing to gastrointestinal compart-
ments.
Following the MVA Gag boost, a significant percentage of
the Mamu-A*01/Gag181-189 tetramer-positive population for
each of the Salmonella-primed animals expressed 
47. While
the 
47 tetramer-positive population was more prominent
in animal 478.99, the animal that made the strongest Gag-
specific CD8 T-cell response, this population was also ob-
served in animal 537.99 at multiple time points (Fig. 4). In
most cases, more than 50% of the tetramer-positive CD8
T-cell population expressed 
47. The tetramer-positive
CD8 T-cell responses in the two animals that received a
single peripheral immunization with MVA Gag were too low
to afford a meaningful comparison. However, Gag-specific
FIG. 3. Gag-specific proliferative responses following immuniza-
tion with a recombinant Salmonella and MVA. PBMC were stimulated
with aldrithiol-2-inactivated SIV or a 1,000-fold concentrate of aldri-
thiol-2-treated microvesicles prepared from uninfected cells. After 7
days, antigen-specific proliferation was determined in a 6-h [3H]thy-
midine incorporation assay. Stimulation indexes represent [3H]thymi-
dine incorporation in response to SIV divided by incorporation in
response to the microvesicle controls. Stimulation index values greater
than 3 are considered positive. Solid arrows indicate the doses of S.
enterica serovar Typhimurium given at weeks 0 and 10, the dashed
arrow indicates the dose of S. enterica serovar Typhi given at week 27,
and the double arrow indicates the MVA Gag inoculation at week 40.
NT indicates that SIV-specific proliferation was not tested.
FIG. 4. Gag-specific CD8 T cells in the peripheral blood of the
Salmonella-primed animals express the mucosal homing receptor

47. PBMC were stained with monoclonal antibodies to CD3, CD8,
and 
47 and with Mamu-A*01 Gag181-189 tetramers and analyzed by
flow cytometry. The percentage of total Gag181-189-specific CD8
 T
cells at each time point is indicated by the black bars, and the fraction
of this population that was also 
47 is indicated by the overlapping
gray bars.
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CD8 T-cell responses stimulated by peripheral DNA prime/
MVA boost regimens were previously shown to be 
47 neg-
ative (10). Thus, these results further suggest that Gag-specific
CD8 T-cell responses were primed in the gastrointestinal
mucosa by the SopE-Gag-recombinant Salmonella strain.
Gag-specific CD8 T cells induced by Salmonella strain/
MVA vaccination home to the colonic mucosa. SIV Gag-spe-
cific CD8 T cells were also observed among lymphocytes
isolated from the colon of Salmonella strain-primed animals.
Lymphocytes were isolated from endoscope-guided pinch bi-
opsies of the colon 4 weeks after the MVA Gag boost (week
44) and stained with Mamu-A*01/Gag181-189 tetramers. A clear
elevation in the Gag-specific CD8 T-cell population was ob-
served in both Salmonella-primed animals (animals 478.99 and
537.99) compared to naïve (animal 252.90) and MVA Gag-
immunized (animal 256.90) Mamu-A*01 control animals
(Fig. 5). Thus, gastrointestinal priming with the SopE-Gag-
secreting recombinant Salmonella followed by boosting intra-
dermally with MVA Gag induced Gag-specific CD8 T-cell
responses that trafficked to the colonic mucosa.
Intrarectal challenge with SIVmac239. Each of the four
immunized animals and two additional Mamu-A*01, naïve
control animals were challenged intrarectally with SIVmac239
at week 50. Both of the Salmonella-primed animals became
infected, and neither exhibited significant differences in peak
or postacute viral loads compared to naïve control animals
(Fig. 6A). Furthermore, both of the Salmonella strain-primed
animals exhibited declining CD4 T-cell counts, similar to
naïve and MVA Gag control animals (Fig. 6B). Thus, we did
not observe any evidence of protection in this pilot study.
Surprisingly, one of the animals immunized with MVA Gag
alone (animal 256.90) did not become infected and re-
mained resistant to infection with a threefold-higher dose of
SIVmac239 administered intrarectally at week 58 (Fig. 6A).
We continued to follow the development of SIV-specific
CD8 T-cell responses in the blood after challenging by stain-
ing with Mamu-A*01/Gag181-189 and Mamu-A*01/Tat28-35 tet-
ramers. With the exception of animal 256.90, each of the im-
munized animals made dramatic secondary CD8 T-cell
responses to Gag. These responses peaked 2 weeks after in-
fection at between 15% and 30% of the CD8 T-cell popula-
tion (Fig. 7) and declined with resolution of primary viremia
(Fig. 6A). In contrast, primary CD8 T-cell responses to SIV
emerged a week later and were much lower in frequency. The
Gag-specific responses in the naïve control animals and the
Tat-specific responses in each of the immunized animals
peaked between 3 and 4 weeks after infection at less than 5%
of the peripheral blood CD8 T-cell population (Fig. 7).
DISCUSSION
Despite recent advances in the development of vaccine ap-
proaches able to induce CTL responses, there is a continuing
need to develop better methods to induce CTL responses able
to home to mucosal sites. We therefore evaluated the potential
of the Salmonella type III secretion system to prime SIV-
specific T-cell responses in the gastrointestinal mucosa of rhe-
sus macaques. The ability of the Salmonella type III secretion
system to deliver SIV Gag polypeptides into rhesus cells for
antigen processing and presentation to CTL was first demon-
strated in vitro. Infection of rhesus B-cell lines with S. enterica
serovar Typhimurium and S. enterica serovar Typhi expressing
SopE-Gag fusions sensitized cells for recognition by Gag-spe-
cific CTL derived from SIV-infected animals. These results
demonstrated that the Salmonella type III secretion system was
capable of delivering polypeptide antigens, not just discrete
CTL epitopes, into the MHC class I antigen-processing path-
way of macaque cells.
Recombinants expressing SopE fusions with shorter Gag
polypeptides were generally recognized better than recombi-
nants expressing fusions with longer Gag sequences, suggesting
that the larger fusion proteins may not be efficiently translo-
cated into host cells. This was particularly evident in CTL
assays with S. enterica serovar Typhi-infected target cells. In-
deed, there was no detectable CTL recognition of the two
largest fusions, SopE-Gag4-507 and SopE-Gag4-439, when they
were expressed by S. enterica serovar Typhi. Similar differences
in CTL recognition of the SopE-Gag fusion proteins were
observed in preliminary assays with S. enterica serovar Typhi-
murium recombinants in rodent cells. These experiments re-
FIG. 5. Homing of Gag-specific CD8 T cells to the colon in Salmonella strain (Sal)-primed macaques. Freshly isolated lymphocytes from
endoscope-guided pinch biopsies of the colon were stained with antibodies to CD3 and CD8 in addition to Mamu-A*01 Gag181-189 tetramers and
analyzed by flow cytometry. After gating on the CD3 CD8 T-cell population, the percentage of CD8 T cells specific for Mamu-A*01/Gag181-189
was determined, as indicated in the upper right quadrants of each plot. More than 100,000 events and at least 6,000 CD3 CD8 T cells were
collected for each sample.
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vealed a trend toward better T-cell recognition of the shorter
SopE-Gag fusion proteins and are consistent with Western
blots showing that the larger SopE-Gag fusion proteins were
not secreted by the Salmonella type III secretion system as
efficiently as the smaller fusion proteins (data not shown). At
present, it is unclear whether these differences in the efficiency
of secretion and antigen presentation reflect differences in the
size of the polypeptide fusions or sequence-specific properties
unique to certain regions of the SIV Gag protein.
Intragastric inoculation of rhesus macaques with attenuated
Salmonella strains expressing selected SopE-Gag fusions also
primed Gag-specific CTL responses in vivo. While CTL re-
sponses to Gag were initially low during the Salmonella-prim-
ing phase, these responses increased dramatically following the
MVA Gag boost. Gag-specific CD8 T-cell frequencies in the
two Salmonella-primed/MVA-boosted animals were similar to
Gag-specific CD8 T-cell frequencies stimulated by early
DNA prime/MVA boost regimens (2, 19). Furthermore, these
responses were higher in the Salmonella-primed animals than
in the animals that received MVA Gag alone. The higher
frequency of Gag-specific CD8 T cells in the two Salmonella-
primed animals is characteristic of a secondary immune re-
sponse and is consistent with the priming of these responses by
SopE-Gag-expressing Salmonella strains.
Following the MVA Gag boost, a fraction of the Gag-spe-
cific CD8 T-cell population in the peripheral blood of each of
the Salmonella-primed animals also expressed the mucosal
homing receptor 
47. The 
47 population was variable but
generally represented 30% to 80% of the total tetramer-posi-
tive population. 
47 is expressed on lymphocytes specific for
gastrointestinal pathogens, and interactions between 
47 and
MadCAM1 on the endothelium of blood vessels serving the
gastrointestinal tract facilitate the trafficking of lymphocytes
into effector sites of the gut-associated lymphoid tissues (9, 18,
32, 42). 
47 CD8 T-cell responses to SIV have been ob-
served in macaques infected with wild-type and live attenuated
strains of the virus (10). This 
47 phenotype probably re-
flects the preferential replication of SIV in activated CD4 T
cells of the intestine (39, 40). In contrast, SIV-specific CD8 T
responses stimulated by a peripheral DNA prime/MVA boost
vaccine regimen were shown to be 
47 negative (10). The
expression of 
47 on Gag-specific CD8 T cells of Salmonel-
la-primed/MVA-boosted animals further supports the gastro-
intestinal priming of these responses by recombinant Salmo-
nella strains. To our knowledge, this represents the first
demonstration of SIV-specific, 
47 CD8 T-cell responses
stimulated by a recombinant mucosal vaccine approach.
FIG. 6. SIV RNA in plasma and CD4 T-cell counts after intra-
rectal challenge with SIVmac239. (A) Plasma viral RNA loads were
determined with a quantitative reverse transcription-PCR assay (24).
This assay has a nominal sensitivity of 100 copy equivalents/ml of
plasma (indicated by the dashed line) and an interassay coefficient of
variation of 25%. (B) CD4 T-cell counts were determined by flow
cytometry as described previously (43). Time points marked with †
indicate the week that an animal was euthanized.
FIG. 7. Postchallenge SIV Gag- and Tat-specific CD8 T-cell re-
sponses. PBMC were stained with monoclonal antibodies to CD3 and
CD8 and with Mamu-A*01/Gag181-189 or Mamu-A*01/Tat28-35 tetra-
mers and analyzed by flow cytometry. After gating on the CD3 CD8
population, the percentage of cells specific for Gag181-189 and Tat28-35
was determined at each time point.
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Consistent with the 
47 phenotype of Gag-specific CD8
T cells in the blood, Gag-specific CD8 T cells were also found
in lymphocytes isolated from endoscope-guided colon biopsies.
Tetramer staining revealed a small but distinct Gag-specific
CD8 T-cell population that was present in colonic lympho-
cytes isolated from the Salmonella-primed animals but not
from naïve or MVA Gag-immunized Mamu-A*01 control
animals. Thus, mucosal priming with recombinant Salmonella
strains followed by an intradermal boost with MVA Gag stim-
ulated CD8 T-cell responses that homed to mucosal surfaces
of the gastrointestinal tract. This analysis did not discriminate
between intraepithelial and lamina propria lymphocyte popu-
lations, both of which were represented in the biopsy samples.
Nevertheless, the presence of Gag-specific CD8 T cells at
such superficial sites is encouraging, since it indicates that the
virus-specific T cells trafficked to mucosal tissues relevant to
the earliest stages of viral transmission.
Despite having stimulated Gag-specific CD8 T-cell re-
sponses in both peripheral and mucosal compartments, ani-
mals immunized with SopE-Gag-recombinant Salmonella were
not protected against an intrarectal challenge with SIVmac239.
Each of the Salmonella-primed animals became infected and
did not differ significantly in peak or postacute viral loads from
control animals. The goal of this pilot study was to evaluate the
potential of the Salmonella type III secretion system to prime
SIV-specific mucosal CTL responses. Thus, the Salmonella and
MVA recombinants were designed to express only Gag
polypeptides and emphasized responses to a single CD8 T-
cell epitope (Mamu-A*01/Gag181-189) that could be detected
easily with available MHC class I tetramers. However, these
responses may not have been diverse enough to contain virus
replication.
Although animals were immunized with a Salmonella strain
expressing both SopE-Gag146-213 and SopE-Gag4-507, the
SopE-Gag4-507 fusion protein was secreted much less efficiently
than SopE-Gag146-213 in Western blot assays on bacterial cul-
ture supernatants (data not shown). Therefore, despite CTL
recognition of SopE-Gag4-507 in S. enterica serovar Typhi-
murium-infected cells in vitro (Fig. 1A), this construct may
have contributed little to the priming of Gag-specific CD8
T-cell responses in vivo. Hence, mucosal priming of CD8
T-cell responses may have been limited to Gag residues 146 to
213 and to the Mamu-A*01/Gag181-189 epitope alone.
An additional explanation for the lack of protection in this
study is the relative weakness of Gag-specific CD8 T-cell
responses. While the responses in the Salmonella strain-
primed/MVA-boosted animals were similar in frequency to
responses achieved by early DNA prime/MVA boost regimens
(2, 19), they were lower than responses stimulated by more
recent, better-optimized regimens (3, 35). Finally, SIVmac239
represents a particularly rigorous challenge virus. Protective
immunity to SIVmac239 has been extremely difficult to elicit
even with multivalent vaccine approaches that stimulate stron-
ger and much broader cellular immunity (20). Thus, it is not
surprising that the narrowly focused and relatively weak cellu-
lar immune responses stimulated in this pilot study failed to
contain virus replication after challenge with SIVmac239.
One of the animals vaccinated with MVA Gag alone (animal
256.90) did not become infected after intrarectal challenge
with SIVmac239. Since this animal remained resistant to a
threefold-higher dose of virus administered 8 weeks later, it is
unlikely that the failure to establish an infection in this animal
simply reflects the odds of virus transmission across the rectal
mucosa with a low-titer virus inoculum. While it is possible that
immunization with MVA Gag may have contributed to the
resistance of 256.90 to SIV infection, this is also unlikely to be
the sole explanation for this result, since such solid protection
against challenge with pathogenic SIVmac strains is rarely, if
ever, observed in animals immunized with recombinant poxvi-
ruses. Resistance to mucosal SIV infection among control an-
imals has been observed in other vaccine studies and often
complicates the interpretation of protection data obtained
from mucosal challenges (29). Thus, some animals may have
an inherent resistance to mucosal infection that is poorly un-
derstood at present (29).
The results of this study suggest that mucosal priming with
vectors such as attenuated Salmonella may direct virus-specific
cellular immune responses to mucosal sites of virus transmis-
sion and early virus replication. However, the T-cell responses
stimulated in this study were insufficient to protect against an
intrarectal challenge with SIVmac239. Having demonstrated
the potential of the Salmonella type III secretion system to
prime SIV-specific CTL responses in macaques, future studies
with additional Salmonella strains and MVA recombinants and
more optimal vaccination protocols can now be designed to
more rigorously evaluate the ability of this approach to provide
protection against viral challenge.
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